Trials / Not Yet Recruiting
Not Yet RecruitingNCT07454850
A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait
Retrospective Study on Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia (CML) in Kuwait
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 400 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 21 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to assess demographics, clinical features, treatment patterns, and the comorbidity burden and its impact on CML patients in the real-world clinical setting in Kuwait. Adult patients with Philadelphia positive-chromosome (Ph+ve) CML who have received at least one line of tyrosine kinase inhibitor (TKI) treatment, such as but not limited to imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib will be included. The study will use data from the hospital records of CML patients between January 2014 and January 2024.
Conditions
Timeline
- Start date
- 2026-05-16
- Primary completion
- 2026-09-19
- Completion
- 2026-09-19
- First posted
- 2026-03-06
- Last updated
- 2026-03-31
Source: ClinicalTrials.gov record NCT07454850. Inclusion in this directory is not an endorsement.